UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the Quarterly Period ended March 31, 2001
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ___________to _________
Commission file number 000-14242
CELSION CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
Delaware 52-1256615
-------- ------------------------
State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization Identification No.)
10220-I Old Columbia Road, Columbia, Maryland 21046-1705
---------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's Telephone Number, Including Area Code (410) 290-5390
--------------
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No ____
As of May 14, 2001, the Registrant had outstanding 76,356,043 shares of Common
Stock, $.01 par value.
1
PART I
FINANCIAL INFORMATION
Item 1. Financial Statements.
Index to Financial Statements
Page
Balance Sheets as of March 31, 2001 and September 30, 2000 3
Statements of Operations for the Three and Six Month Periods 5
Ended March 31, 2001 and March 31, 2000
Statements of Cash Flows for the Six Month Periods Ended March 6
31, 2001 and 2000
Notes to Financial Statements 7
2
CELSION CORPORATION
BALANCE SHEETS
as of March 31, 2001 and September 30, 2000
ASSETS
March 31, 2001
(Unaudited) September 30, 2000
Current assets:
Cash and cash equivalents $ 6,132,250 $ 8,820,196
Accounts receivable - trade 2,922 2,307
Accrued interest receivable -- 7,751
Inventories 17,993 13,538
Prepaid expenses 105,528 22,417
Other current assets
134,356 34,356
----------- -----------
Total current assets 6,393,049 8,900,565
----------- -----------
Property and equipment - at cost:
Furniture and office equipment 186,948 146,287
Laboratory and shop equipment 86,969 52,978
Less accumulated depreciation 97,123 74,540
----------- -----------
Net value of property and equipment 176,794 124,725
----------- -----------
Other assets:
Patent licenses (net of amortization ) 84,617 92,531
----------- -----------
Total assets $ 6,654,460 $ 9,117,821
=========== ===========
See accompanying notes.
3
LIABILITIES AND STOCKHOLDERS' EQUITY
March 31, 2001 September 30, 2000
Current liabilities:
Accounts payable - trade $ 55,190 $ 60,472
Notes payable 111,591 114,778
Accrued interest payable -- 155,373
Other accrued liabilities 69,250 60,769
----------- -----------
Total current liabilities 236,031 391,392
----------- -----------
Stockholders' equity:
Common stock $.01 par value - 150,000,000 shares
authorized, 76,287,567 and 64,372,067 shares
issued and outstanding for March 31,2001 and
September 30,2000 respectively; 762,876 643,721
Series A 10% Convertible Preferred Stock - $1,000
par value, 7,000 shares authorized, 1,147 and 5,176
shares issued and outstanding for March 31,2001
and September 30,2000, respectively; 1,147,380 5,176,000
Additional paid-in capital 34,094,977 29,354,125
Accumulated deficit (29,586,804) (26,447,417)
----------- -----------
Total stockholders' equity 6,418,429 8,726,429
----------- -----------
Total liabilities and stockholders' equity $ 6,654,460 $ 9,117,821
=========== ===========
See accompanying notes.
4
CELSION CORPORATION
STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Six Months
Ended March 31, Ended March 31,
------------------------- -------------------------
2001 2000 2001 2000
----------- ----------- ----------- -----------
Revenue:
Hyperthermia sales
and parts $ 1,858 $ 3,465 $ 1,858 $ 3,465
----------- ----------- ----------- -----------
Total revenue 1,858 3,465 1,858 3,465
----------- ----------- ----------- -----------
Cost of sales -- -- -- --
Gross profit 1,858 3,465 1,858 3,465
----------- ----------- ----------- -----------
Operating expenses:
General and
administrative 982,792 746,368 1,913,951 1,232,832
Research and
development 669,820 400,195 1,248,321 755,774
----------- ----------- ----------- -----------
Total operating
expenses 1,652,612 1,146,563 3,162,272 1,988,606
----------- ----------- ----------- -----------
Loss from operations (1,650,754) (1,143,098) (3,160,414) (1,985,141)
Other income 94,883 60,750 207,459 68,441
Interest expense -- (188) (53) (499)
----------- ----------- ----------- -----------
Loss before income (1,555,871) (1,082,536) (2,953,008) (1,917,199)
taxes
Income taxes -- -- -- --
----------- ----------- ----------- -----------
Net loss (1,555,871) (1,082,536) (2,953,008) (1,917,199)
=========== =========== =========== ===========
Net loss per common
share (basic) ($0.02) ($0.02) ($0.04) ($0.03)
=========== =========== =========== ===========
Weighted average
shares outstanding 71,109,723 56,424,722 67,775,376 55,120,781
=========== =========== =========== ===========
See accompanying notes.
5
CELSION CORPORATION
STATEMENTS OF CASH FLOWS
(Unaudited)
Six Months Ended March 31,
2001 2000
----------- -----------
(Unaudited) (Unaudited)
Cash flows from operating activities:
Net loss $(2,953,008) $(1,917,199)
Noncash items included in net (loss) income:
Depreciation and amortization 30,498 17,082
Stock based compensation 313,591 --
Preferred shares converted into common stock 216,416 --
Net changes in:
Accounts receivable 7,136 (10,012)
Inventories (4,455) --
Prepaid expenses (83,111) (189,619)
Other current assets (100,000) (36,197)
Accounts payable-trade (5,282) 102,298
Accrued interest payable (155,373) (13,800)
Accrued compensation -- (91,009)
Other accrued liabilities and deferred revenue 5,294 93,852
----------- -----------
Net cash used by operating activities (2,728,294) (2,044,604)
----------- -----------
Cash flows from investing activities:
Purchase of property and equipment (74,652) (53,525)
----------- -----------
Net cash used by investing activities (74,652) (53,525)
----------- -----------
Cash flows from financing activities:
Payment on notes payable (net) -- (10,000)
Payment on capital leases (net) -- (638)
Proceeds of stock issuances 115,000 10,370,579
----------- -----------
Net cash provided by financing activities 115,000 10,359,941
----------- -----------
Net (decrease) increase in cash (2,687,946) 8,261,812
Cash at beginning of period 8,820,196 1,357,464
----------- -----------
Cash at end of the period $ 6,132,250 $ 9,619,276
=========== ===========
See accompanying notes.
6
CELSION CORPORATION
NOTES TO FINANCIAL STATEMENTS
Note 1. Basis of Presentation
The accompanying unaudited condensed financial statements, which
include the accounts of Celsion Corporation (the "Company"), have been prepared
in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments, consisting
only of normal recurring accruals considered necessary for a fair presentation,
have been included in the accompanying unaudited financial statements. Operating
results for the six months ended March 31, 2001 are not necessarily indicative
of the results that may be expected for the full year ending September 30, 2001.
For further information, refer to the financial statements and notes thereto,
included in the Company's Annual Report on Form 10-K for the fiscal year ended
September 30, 2000.
Note 2. Common Stock Outstanding and Per Share Information
For the quarters and six-month periods ended March 31, 2001 and 2000,
per share data is based on the weighted average number of shares of Common Stock
outstanding. Outstanding warrants and options which can be converted into Common
Stock are not included as their effect is anti-dilutive.
Note 3. Inventories
Inventories are carried at the lower of actual cost or market, and cost
is determined using the average cost method. Parts held in inventory as of March
31, 2001 are held as replacements and spares for occasional repair of older
systems sold in previous years.
The components of inventories as of March 31, 2001 and September 30,
2000 are as follows:
March 31, 2001 September 30, 2000
-------------- ------------------
Materials $ 6,985 $ 5,059
Work - in - process 11,008 8,479
-------- ----------
Finished products $ 17,993 $ 13,538
======== =========
7
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations.
Forward-Looking Statements
Statements and terms such as "expect", "anticipate", "estimate",
"plan", "believe" and words of similar import, regarding the Company's
expectations as to the development and effectiveness of its technology, the
potential demand for its products, and other aspects of its present and future
business operations, constitute forward looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Although the Company
believes that its expectations are based on reasonable assumptions within the
bounds of its knowledge of its business and operations, the Company cannot
guarantee that actual results will not differ materially from its expectations.
In evaluating such statements, readers should specifically consider the various
factors contained in the Company's Annual Report on Form 10-K for the fiscal
year ended September 30, 2000, which could cause actual results to differ
materially from those indicated by such forward-looking statements, including
those set forth in "Management's Discussion and Analysis of Financial Condition
and Results of Operations--Risk Factors", as well as those set forth below and
elsewhere in this Report. These factors included, but are not limited to
unforeseen changes in the course of research and development activities and in
clinical trials; possible changes in cost and timing of development and testing,
capital structure, and other financial items; changes in approaches to medical
treatment; introduction of new products by others; possible acquisitions of
other technologies, assets or businesses; and possible actions by customers,
suppliers, competitors, regulatory authorities.
General
Since inception, the Company has incurred substantial operating losses.
The Company expects operating losses to continue and possibly increase in the
near term and for the foreseeable future as it continues its product development
efforts, conducts clinical trials and undertakes marketing and sales activities
for new products. The Company's ability to achieve profitability is dependent
upon its ability successfully to integrate new technology into its thermotherapy
systems, conduct clinical trials, obtain governmental approvals, and
manufacture, market and sell its new products. Major obstacles facing the
Company over the last several years have included inadequate funding, a negative
net worth, and the slow development of the thermotherapy market due to technical
shortcomings of the thermotherapy equipment available commercially. The Company
has not continued to market its older thermotherapy system, principally because
of the system's inability to provide heat treatment for other than surface and
sub-surface tumors, and has concentrated its efforts on a new generation of
thermotherapy products.
The operating results of the Company have fluctuated significantly in
the past on an annual and a quarterly basis. The Company expects that its
operating results will fluctuate significantly from quarter to quarter in the
future and will depend on a number of factors, many of which are outside the
Company's control.
8
Results of Operations
Comparison of Three Months Ended March 31, 2001
and Three Months Ended March 31, 2000
Revenue decreased to $1,858 for the three months ended March 31, 2001
compared to $3,465 for the three months ended March 31, 2000. No significant new
product revenues are expected until such time, if any, as the Company's
equipment incorporating new technologies receives the necessary approvals from
governmental regulatory agencies. The new equipment is currently in pivotal
Phase II clinical testing.
General and administrative expense increased by 32% to $982,792 for the
three months ended March 31, 2001, from $746,368 for the comparable period in
2000. The increase of $236,424 was due primarily to increased staff, consulting,
travel, and legal expenses. The Company also expanded and upgraded its office
space, to accommodate increased staff, resulting in an increase in rent.
Research and development expense increased by 67% to $669,820 for the
current period from $400,195 for the three months ended March 31, 2000. The
increase in 2001 expenditure was mainly due to the cost of engineering of the
Company's BPH and breast cancer treatment equipment. The Company expects
expenditures on research and development to increase for the remainder of the
current fiscal year as it continues pivotal Phase II clinical trials for its
breast cancer and BPH treatment systems.
The increased expenditures, discussed above, resulted in an increase in
the loss from operations for the three month period ended March 31, 2001 of
$507,656, to ($1,650,754) from $(1,143,098) in the comparable period during the
prior year.
Comparison of Six Months Ended March 31, 2001
and Six Months Ended March 31, 2000
Revenue decreased to $1,858 for the six months ended March 31, 2001
compared to $3,465 for the six months ended March 31,2000. No significant new
product revenues are expected until such time, if any, as the Company's
equipment incorporating new technologies receives the necessary approvals from
governmental regulatory agencies. The new equipment is currently in pivotal
Phase II clinical testing.
General and administrative expense increased by 55% to $1,913,951 for
the six months ended March 31, 2001, from $1,232,832 for the comparable period
in 2000. The increase of $681,119 was due primarily to increased staff,
consulting, travel, legal expenses and costs associated with a registration
statement filed by the Company and subsequently withdrawn in December 2000. The
Company also expanded and upgraded its office space, to accommodate increased
staff, resulting in an increase in rent.
Research and development expense increased by 65% to $1,248,321 for the
current period from $755,774 for the six months ended March 31, 2000. The
increase in 2001 expenditure was mainly due to the cost of engineering of the
Company's BPH and breast cancer treatment equipment. The Company expects
expenditures on research and development to increase for the remainder of the
current fiscal year as it continues pivotal Phase II clinical trials for its
breast cancer and BPH treatment systems.
9
The increased expenditures discussed above resulted in an increase in
the loss from operations for the six month period ended March 31, 2001 of
$1,175,273, to ($3,160,414) from $(1,985,141) in the comparable period during
the prior year.
Liquidity and Capital Resources
Since inception, the Company's expenses have significantly exceeded its
revenues, resulting in an accumulated deficit of ($29,586,804) at March 31,
2001. The Company has incurred negative cash flows from operations since its
inception, and has funded its operations primarily through the sale of equity
securities. As of March 31, 2001, the Company had total current assets of
$6,393,049, including cash and cash equivalents of $6,132,250, current
liabilities of $236,031 and a working capital surplus of $6,157,018. As of
September 30, 2000, the Company had total current assets of $8,900,565,
including cash and cash equivalents of $8,820,196, current liabilities of
$391,392, and a working capital surplus of $8,509,173. Net cash used in the
Company's operating activities was $2,728,294 for the six months ending March
31, 2001.
The Company does not have any bank financing arrangements and has
funded its operations in recent years primarily through private placement
offerings. For all of fiscal year 2001, the Company expects to expend a total of
about $7 million for research, development and administration, of which
approximately $2,728,294 had been expended during the six months ended March 31,
2001. This aggregate expenditure amount is an estimate based upon assumptions
such as, the scheduling and cost of institutional clinical research and testing
personnel, the timing of clinical trials and other factors, not all of which are
fully predictable or within the control of the Company. Accordingly, estimates
and timing concerning projected expenditures and programs are subject to change.
The Company expects to meet its funding needs for fiscal year 2001 from
its current resources.
The Company's dependence on raising additional capital will continue at
least until such time, if any, as the Company is able to begin marketing its new
technologies. The Company's future capital requirements and the adequacy of its
financing depend upon numerous factors, including the successful
commercialization of its thermotherapy systems, progress in its product
development efforts, progress with pre-clinical studies and clinical trials, the
cost and timing of production arrangements, the development of effective sales
and marketing activities, the cost of filing, prosecuting, defending and
enforcing intellectual property rights, competing technological and market
developments, and the development of strategic alliances for the marketing of
its products. The Company will be required to obtain such funding through equity
or debt financing, strategic alliances with corporate partners and others, or
through other sources not yet identified. The Company does not have any
committed sources of additional financing and cannot guarantee that additional
funding will be available in a timely manner, or on acceptable terms, if at all.
If adequate funds are not available in a timely manner and on acceptable terms,
the Company may be required to delay, scale back or eliminate certain aspects of
its operations or attempt to obtain funds through arrangements with
collaborative partners or others that may require the Company to relinquish
rights to certain of its technologies, product candidates, products or potential
markets.
10
Item 3. Quantitative and Qualitative Disclosure About Market Risk.
Not applicable.
PART II
OTHER INFORMATION
Item 1. Legal Proceedings.
On April 27, 2000, we commenced an action in the United States District
Court for the District of Maryland against Warren C. Stearns, a former director,
Mr. Stearn's management company, SMC, and a number of Mr. Stearns' family
members and colleagues who hold certain warrants for the purchase of
approximately 3.4 million shares of our Common Stock. These warrants were
intended as compensation for certain investment banking, brokerage and financing
services rendered and to be rendered by Mr. Stearns and SMC. We have reviewed
with our attorneys the circumstances surrounding the issuance of these warrants
and the services that were performed or purported to be performed by Mr. Stearns
and SMC, and have concluded that these warrants should be rescinded. We believe
that the issuance of these warrants was in violation of Section 15 of the
Securities and Exchange Act of 1934 and constitutes a voidable transaction under
the provisions of Section 29 of that Act.
The defendants in the litigation have moved to dismiss the complaint on
various technical grounds, including statute of limitations. On January 18,
2001, the Maryland District Court denied the defendants' motion to dismiss for
lack of personal jurisdiction but granted the defendants' motion that venue was
improper. The Maryland District Court transferred the matter to the United
States District Court for the Northern District of Illinois, in Chicago, and
referred the remaining grounds for dismissal raised in the defendants' motion to
dismiss to the Illinois District Court.
Item 2. Change in Securities.
During the fiscal quarter ended March 31, 2001, the Company issued the
following securities without registration under the Securities Act of 1933, as
amended (the "Securities Act"):
1. At various times during the quarter, the Company issued a total of
360,000 shares of its Common Stock for a cash consideration of $115,000
upon exercise of stock options and warrants. These shares are
restricted stock, endorsed with the Company's standard restricted stock
legend, with a stop transfer instruction recorded by the transfer
agent. Accordingly, the Company views the shares issued as exempt from
registration under Sections 4(2) and/or 4(6) of the Securities Act. The
cash consideration received by the Company was added to working capital
to be used for general corporate purposes.
11
2. At various times during the quarter, the Company issued a total of
11,439,933 shares of its Common Stock upon conversion of 4,690 shares
of its Series A 10% Convertible Preferred Stock. These shares are
restricted stock, endorsed with the Company's standard restricted stock
legend, with a stop transfer instruction recorded by the transfer
agent. Accordingly, the Company views the shares issued as exempt from
registration under Sections 3(a)(9), 4(2) and/or 4(6) of the Securities
Act.
Item 3. Defaults upon Senior Securities.
Not applicable.
Item 4. Submission of Matters to a Vote of Securities Holders.
Not applicable.
Item 5. Other Information.
Not applicable.
Item 6. Exhibits and Reports on Form 8-K .
(b) Exhibits.
(b) Computation of per share earnings.
(b) Reports on Form 8-K.
None.
12
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DATE: May 14, 2001
CELSION CORPORATION
-------------------
(Registrant)
By: /s/ Spencer J. Volk
-----------------------
Spencer J. Volk
President and Chief Executive Officer
By: /s/ Anthony P. Deasey
--------------------------
Anthony P. Deasey
Chief Financial Officer
13
EXHIBIT 11
CELSION CORPORATION
COMPUTATION OF EARNINGS PER SHARE
Three Months Ended March 31,
2001 2000
Net (loss) income ($1,555,871) ($1,082,536)
Net (loss) income per common share* ($0.02) ($0.02)
Weighted average shares outstanding 71,109,723 56,424,722
* Common stock equivalents have been excluded from the calculation of net loss
per share as their inclusion would be anti-dilutive.